In yesterday’s Wall Street session, Voyager Therapeutics Inc. (NASDAQ:VYGR) shares traded at $8.13, up 10.76% from the previous session.
7 analysts cover Voyager Therapeutics Inc. (NASDAQ:VYGR), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $12.00 and a low of $9.00, we find $10.00. Given the previous closing price of $7.34, this indicates a potential upside of 36.24 percent. VYGR stock price is now 4.78% away from the 50-day moving average and 26.36% away from the 200-day moving average. The market capitalization of the company currently stands at $310.00M.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
The stock has received a hold rating from 4 analysts and a buy rating from 2. Brokers who have rated the stock have averaged $10.25 as their price target over the next twelve months.
With the price target enhanced from $6 to $9, Robert W. Baird Upgraded its rating from Neutral to Outperform for Voyager Therapeutics Inc. (NASDAQ: VYGR). On February 26, 2021, Robert W. Baird Downgraded its previous ‘Outperform’ rating to ‘Neutral’ on the stock reducing its target price from $18 to quote $6, while ‘Wedbush’ rates the stock as ‘Neutral’.
In other news, NEUROCRINE BIOSCIENCES INC, 10% Owner bought 4,395,588 shares of the company’s stock on Feb 23. The stock was bought for $39,032,821 at an average price of $8.88. Upon completion of the transaction, the 10% Owner now directly owns 8,575,316 shares in the company, valued at $69.72 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 17, Senior VP & General Counsel Hesslein Robert W. sold 3,297 shares of the business’s stock. A total of $24,563 was realized by selling the stock at an average price of $7.45. This leaves the insider owning 106,610 shares of the company worth $0.87 million. Insiders disposed of 4,157,923 shares of company stock worth roughly $33.8 million over the past 1 year. A total of 0.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in VYGR stock. A new stake in Voyager Therapeutics Inc. shares was purchased by RAYMOND JAMES & ASSOCIATES during the first quarter worth $894,000. UBS ASSET MANAGEMENT AMERICAS INC invested $398,000 in shares of VYGR during the first quarter. In the first quarter, 683 CAPITAL MANAGEMENT, LLC acquired a new stake in Voyager Therapeutics Inc. valued at approximately $255,000. JANE STREET GROUP, LLC acquired a new stake in VYGR for approximately $204,000. ERGOTELES LLC purchased a new stake in VYGR valued at around $198,000 in the second quarter. In total, there are 90 active investors with 61.20% ownership of the company’s stock.
On Wednesday morning Voyager Therapeutics Inc. (NASDAQ: VYGR) stock kicked off with the opening price of $7.28. During the past 12 months, Voyager Therapeutics Inc. has had a low of $4.61 and a high of $10.81. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.00, and a quick ratio of 2.00. The fifty day moving average price for VYGR is $7.76 and a two-hundred day moving average price translates $6.43 for the stock.
The latest earnings results from Voyager Therapeutics Inc. (NASDAQ: VYGR) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at $0.45, beating analysts’ expectations of -$0.32 by 0.77. This compares to $0.15 EPS in the same period last year. The net profit margin was -24.20% and return on equity was -22.00% for VYGR. The company reported revenue of $-1.55 million for the quarter, compared to $28.07 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -105.52 percent. For the current quarter, analysts expect VYGR to generate $4.19M in revenue.
Voyager Therapeutics Inc.(VYGR) Company Profile
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company’s lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson’s disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington’s disease; VY-FXN01 for Friedreich’s ataxia; and Tau program for the treatment of tauopathies, including Alzheimer’s disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
